Inovio Pharmaceuticals Inc. (NASDAQ:INO), whose market cap now stands at $665.84M, reported EPS of $-1.21 in the last financial year. That implies the stock has price-to-earnings ratio or P/E ratio of – at the prevailing stock price. This year’s EPS is expected to grow -135.30%% over the previous year.
For perspective on the forward P/E metric, analysts on the average have a 12-month price target of $10.80 on the stock of Inovio Pharmaceuticals, Inc..
Over the last five years, Inovio Pharmaceuticals, Inc. has posted EPS improvement of -15.80%. That compared sales growth of 29.30% over the same five-year period.
Let?s look into the charts of the stock
The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.
The company generated free cash flow of $(16.02M).
Inovio Pharmaceuticals, Inc. also reported return assets of -49.00%, return on of -66.10% and return on investments of -61.80%.
Analysts are expecting the stock of Inovio Pharmaceuticals, Inc. to be trading at $10.80 in the next 12 months, but far has it come and what been the quality of its performance?
The stock jumped/declined 20.22% in the past week, and for the past month it is up/down 27.84%. For the quarter and for the year so far, the stock is risen/decline 25.80% and 25.07%, respectively. From a year-ago, the stock has moved -22.01%.
What about the volatility of the stock? First, the stock?s better is beta, a measure of volatility is 2.77. Investors would do well to remember that beta of less than one implies that the underlying security is less volatile compared with the market, but beta greater than one indicates that a security is more volatile than the market.
In terms of weekly or monthly volatility, Inovio Pharmaceuticals, Inc. has a weekly volatility of 5.91% and monthly volatility of 4.53%.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.